3 December 2025
The PSNZ Paediatric Neurodevelopment Clinical Network has submitted a proposal to PHARMAC supporting the funding of Rubifen LA, a new generic methylphenidate brand.
This addition to the medication landscape addresses ongoing supply shortages that have affected young people with ADHD and narcolepsy since September 2023, while also preparing for regulatory changes coming in February 2026.
Read our full submission on why increased medication choices strengthen equitable access to evidence-based ADHD treatment below 👇